<a href="https://laohu8.com/S/PURE">PURE Bioscience</a> Q1 net loss narrows to USD 464,000 as revenue rises 27% to USD 708,000
PURE Biosciences Inc. reported its financial results for the fiscal first quarter ended October 31, 2025. The company posted net product sales of USD 0.71 million for the period. Total revenue, including royalty revenue, reached USD 0.71 million. Cost of goods sold amounted to USD 0.26 million, resulting in a gross profit of USD 0.45 million. Selling, general and administrative expenses were USD 0.74 million, and research and development expenses totaled USD 0.09 million. Total operating costs and expenses were USD 0.83 million. The company reported a loss from operations of USD 0.38 million and a net loss of USD 0.46 million for the quarter. Basic and diluted net loss per share was USD 0.00, with 111,886,473 shares used in the calculation.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PURE Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251215068126) on December 15, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。